Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Posts Revenue Gains, Narrowed Loss in Q3

NEW YORK, Oct. 28 - Gene Logic today said that an increase in GeneExpress subscribers helped boost third-quarter revenue by 23 percent. In addition, despite a boost in R&D spending and overall expenses, net loss in the quarter narrowed.


For the three-month period ended Sept. 30, Gene Logic reported $14.2 million in total receipts, up from $11.5 for the same quarter one year ago.


R&D spending in the quarter grew to $17.3 million from $14.5 million in the third quarter last year, and SG&A fell to $4.3 million in the current quarter from $4.7 million year over year, the company said.


Net loss narrowed during the third quarter to $7 million, or $.26 per share, from $7.2 million, or $.27 per share, year over year.


Gene Logic said it had roughly $171.9 million in cash and cash equivalents as of Sept. 30.


Click here for more information.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.